SOURCE
Psychiatry Investigation. 18 (1) (pp 1-10), 2021. Date of Publication: 2021.
AUTHORS
Park M.J.; Kim H.; Kim E.J.; Yook V.; Chung I.W.; Lee S.M.; Jeon H.J.
OBJECTIVE
Electro-convulsive therapy (ECT) has been established as a treatment modality for patients with treatment-resistant depression and with some specific subtypes of depression. This narrative review intends to provide psychiatrists with the latest findings on the use of ECT in depression, dIvided into total eight sub-topics.
METHODS
We searched PubMed for English-language articles using combined keywords and tried to analyze journals published from 1995-2020.
RESULTS
Pharmacotherapy such as antidepressants or maintenance ECT is more effective than a placebo as prevention of recurrence after ECT. The use of ECT in treatment-resistant depression, depressed patients with suicidal risks, elderly depression, bipolar depression, psychotic depression, and depression during pregnancy or postpartum have therapeutic benefits. As possible mechanisms of ECT, the role of neurotransmitters such as serotonin, dopamine, gamma-aminobutyric acid (GABA), and other findings in the field of neurophysiology, neuro-immunology, and neurogenesis are also supported.
CONCLUSION
ECT is evolving toward reducing cognitive side effects and maximizing therapeutic effects. If robust evidence for ECT through randomized controlled studies are more established and the mechanism of ECT gets further clarified, the scope of its use in the treatment of depression will be more expanded in the future.
